Medical College, Guizhou University, Huaxi District, Guiyang, 550025, Guizhou, China.
School of Life Science and Technology, University of Electronic Science and Technology of China, No.2006, Xiyuan Ave, West Hi-Tech Zone, Chengdu, 6173001, Sichuan, China.
Interdiscip Sci. 2023 Dec;15(4):578-589. doi: 10.1007/s12539-023-00575-x. Epub 2023 Jun 30.
CD47/SIRPα pathway is a new breakthrough in the field of tumor immunity after PD-1/PD-L1. While current monoclonal antibody therapies targeting CD47/SIRPα have demonstrated some anti-tumor effectiveness, there are several inherent limitations associated with these formulations. In the paper, we developed a predictive model that combines next-generation phage display (NGPD) and traditional machine learning methods to distinguish CD47 binding peptides. First, we utilized NGPD biopanning technology to screen CD47 binding peptides. Second, ten traditional machine learning methods based on multiple peptide descriptors and three deep learning methods were used to build computational models for identifying CD47 binding peptides. Finally, we proposed an integrated model based on support vector machine. During the five-fold cross-validation, the integrated predictor demonstrated specificity, accuracy, and sensitivity of 0.755, 0.764, and 0.772, respectively. Furthermore, an online bioinformatics tool called CD47Binder has been developed for the integrated predictor. This tool is readily accessible on http://i.uestc.edu.cn/CD47Binder/cgi-bin/CD47Binder.pl .
CD47/SIRPα 通路是继 PD-1/PD-L1 之后肿瘤免疫领域的新突破。虽然目前针对 CD47/SIRPα 的单克隆抗体疗法已经显示出一些抗肿瘤效果,但这些制剂存在几个固有的局限性。在本文中,我们开发了一个预测模型,该模型结合了下一代噬菌体展示(NGPD)和传统的机器学习方法来区分 CD47 结合肽。首先,我们利用 NGPD 生物淘选技术筛选 CD47 结合肽。其次,基于多种肽描述符的十种传统机器学习方法和三种深度学习方法被用于建立识别 CD47 结合肽的计算模型。最后,我们提出了一种基于支持向量机的集成模型。在五重交叉验证中,集成预测器的特异性、准确性和敏感性分别为 0.755、0.764 和 0.772。此外,还开发了一个名为 CD47Binder 的在线生物信息学工具,用于集成预测器。该工具可在 http://i.uestc.edu.cn/CD47Binder/cgi-bin/CD47Binder.pl 上访问。